Happy to share our most recent, open-access publication ”Cost-Effectiveness Analysis of Upadacitinib in Patients With Moderately to Severely Active Ulcerative Colitis in Greece ” in Value in Health Regional Issues.

Ulcerative Colitis (UC) is a chronic inflammatory bowel disease (IBD) defined by relapsing-remitting colonic mucosa inflammation or a chronic active course . UC patients often experience distressing, unpredictable gastrointestinal symptoms, comorbidities and treatment-related adverse events.

The present study aimed to investigate the cost-effectiveness of upadacitinib compared with other available biologics and small molecule agents in adult Greek patients with moderately to severely active ulcerative colitis, who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent from a public payer perspective. Our analysis reported that, upadacitinib was estimated to be the most effective and cost-effective treatment among all advanced treatments for moderately to severely active ulcerative colitis in Greece.

Find more at: Value in Health Regional Issues